BOLD-100 / Bold Therap, Hana Pharm - LARVOL DELTA

Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against chemotherapy-induced peripheral neuropathy (AACR 2026) - P1/2 | "To assess BOLD-100's neuroprotective effects in vivo, Sprague-Dawley rats received vehicle (10 mL/kg), oxaliplatin (1.5 mg/kg), paclitaxel (1.0 mg/kg), or BOLD-100 (40 mg/kg) alone, plus BOLD-100 in combination with oxaliplatin and paclitaxel...Chemotherapy-induced peripheral neuropathies have limited therapeutic options; these results demonstrate BOLD-100's potential for both neuroprotection and treatment via impacting important stress pathways. Ongoing clinical study BOLD-100-001 is assessing BOLD-100's neuroprotective effects and its ability to enhance patient outcomes and reduce neurotoxicity."

Clinical • Biliary Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ATF6 • HSPA5

BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrialsregister.eu) - P1/2 | N=52 | Recruiting | Sponsor: Bold Therapeutics Inc.

New P1/2 trial • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRAF

BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrialsregister.eu) - P1/2 | N=52 | Recruiting | Sponsor: Bold Therapeutics Inc. | N=38 ➔ 52

Enrollment change • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRAF

Bold-100-001: A randomized phase 2 study of bold-100 plus FOLFOX vs FOLFOX in patients with refractory metastatic colorectal cancer. (ASCO-GI 2026) - P1/2 | "Prior oxaliplatin is permitted if: 1) received in the adjuvant setting; 2) received in first line setting with no progression on treatment or within 3 months of oxaliplatin treatment cessation...120 patients are expected to be enrolled. Enrollment is ongoing at sites in Canada, South Korea and Europe."

Clinical • Metastases • P2 data • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS

Additional functionality for plecstatin-1-analogous anticancer Ru(η6-p-cymene)Cl complexes. (PubMed, J Inorg Biochem) - "Complexes 1a-3a showed no activity but 4a was moderately potent with an IC50 value of 35 μM in NCI-H460 cells. Organoruthenium compound 4a was also more active than its PCA ligand 4 and the clinically investigated Ru complex KP1339 in NCI-H460 cells."

Journal • Cervical Cancer • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BOLDSARC-01: BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: University Health Network, Toronto | Initiation date: Jun 2025 ➔ Mar 2026

Trial initiation date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

The Role of Metallodrugs in Enhancing Neuroendocrine Neoplasm Therapies: The Promising Anticancer Potential of Ruthenium-Based Complexes. (PubMed, Molecules) - "Currently, medicinal inorganic chemistry is investigating new metal-based drugs to mitigate the side effects of existing agents, including cisplatin and its derivative compounds. This review focuses on the promising antitumor effects of certain Ru compounds in NEN therapy, emphasizing their potential in NEN treatment through interaction with new potential targets. Among these, IT-139 (also known as KP-1339 or NKP-1339), which has already entered clinical trials, and other new Ru compounds are highlighted."

Journal • Review • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy. (PubMed, Biomater Res) - "Moreover, the UTMD technique enhanced the tumoral accumulation and penetration of nanobubbles, improving delivery specificity and minimizing off-target effects. This combined treatment strategy, including UTMD, provides a promising translational potential for ESCC therapy."

IO biomarker • Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gene Therapies • Metabolic Disorders • Oncology • Solid Tumor • Squamous Cell Carcinoma • CALR • CD8 • MIR142 • PD-1 • PD-L1

Machine Learning-Enhanced Calculation of Quantum-Classical Binding Free Energies. (PubMed, J Chem Theory Comput) - "The ML potential approach takes electrostatic embedding and long-range electrostatics into account. We demonstrate the applicability of the workflow on the well-studied protein-ligand complex of myeloid cell leukemia 1 and the inhibitor 19G and on the anticancer drug NKP1339 acting on the glucose-regulated protein 78."

Journal • Hematological Malignancies • Leukemia • Oncology • MCL1

Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma. (PubMed, Cell Commun Signal) - "BOLD-100 synergizes with AZD6738, an ATR inhibitor, to enhance anti-tumor efficacy compared to either agent alone in both in vitro and in vivo models. These findings suggest that BOLD-100, especially in combination with an ATR inhibitor, represents a promising therapeutic option for patients with PDAC."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CHEK1 • HSPA5

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: University Health Network, Toronto

New P1 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study. (PubMed, Invest New Drugs) - "Our aim is to investigate cellular responses of several PM cell lines to a regimen that includes BOLD-100 in addition to other commonly used treatments. BOLD-100 is a ruthenium-based anticancer therapeutic."

Journal • Preclinical • Gastrointestinal Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor • HSPA5

Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025 (PRNewswire) - P1b/2a | N=220 | NCT04421820 | Sponsor: Bold Therapeutics, Inc. | "A surprising finding from this trial was a profound reduction in both the frequency and severity of oxaliplatin-induced peripheral neuropathy (OIPN), a relatively common and debilitating side effect of chemotherapy. In each patient cohort, rates of neuropathy were dramatically lower than those typically seen in historical benchmarks for FOLFOX alone: These results were supported by feedback from trial investigators, many of whom noted the unexpectedly low incidence of neuropathy in their patients treated with BOLD-100 — particularly those who were heavily pretreated and/or receiving FOLFOX again where one would expect both a high incidence and severity of neuropathy."

P1/2 data • Biliary Tract Cancer • Colorectal Cancer • Gastric Cancer • Pancreatic Ductal Adenocarcinoma

Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) (PRNewswire) - "Bold Therapeutics Inc...announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent neuroprotective properties at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30, 2025, in Chicago, Illinois. Mark Bazett will be joined by Jim Pankovich, EVP Clinical Development, and Ashish Kumar, PhD, Sr. Scientist....Bold Therapeutics is currently enrolling FOLFOX-naïve second-line mCRC patients in a multinational randomized clinical study comparing FOLFOX vs. FOLFOX + BOLD-100 in various efficacy, safety, and quality-of-life endpoints. Bold Therapeutics anticipates this trial will further demonstrate BOLD-100's potential as a transformative therapy in early-line colorectal cancer, biliary tract cancer and other solid tumor indications."

Late-breaking abstract • Preclinical • Trial status • Biliary Tract Cancer • Colorectal Cancer • Solid Tumor

Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3. (PubMed, Cell Commun Signal) - "This was associated with increased cholesterol uptake/biosynthesis and decreased sensitivity to the ruthenium-based anticancer drug BOLD-100. Overall, the present study contributes to shedding light on the molecular pathways connecting mechanical cues, tumor metabolism and drug responsiveness."

Journal • Preclinical • Epithelial Ovarian Cancer • Metabolic Disorders • Oncology • Ovarian Cancer • Solid Tumor • YAP1

Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model (AACR 2025) - P1/2 | "Collectively, these findings provide strong evidence that BOLD-100 not only enhances oxaliplatin-based therapy in GI malignancies but also improves its clinical utility by markedly reducing OIPN. Ongoing clinical studies are evaluating BOLD-100's neuroprotective benefits and its potential to enhance the therapeutic index of standard-of-care regimens for advanced GI cancers."

Late-breaking abstract • Preclinical • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

PERK as a biomarker to optimize therapy of GRP78 inhibitor, BOLD-100, in gastric cancer (AACR 2025) - "BOLD-100 (GRP78 inhibitor), TUDCA (Tauroursodeoxycholic acid; ER stress inhibitor), and AZD6738 (ATR inhibitor) were used. The expression of PERK determines sensitivity to GRP78 inhibition by BOLD-100 in GC. PERK-high GC cells are sensitive to BOLD-100 and show efficacy as monotherapy. In PERK-low GC cells, the combination of BOLD-100 and ATR inhibitor is an optimal therapeutic option for GC treatment."

Biomarker • Gastric Cancer • Oncology • Solid Tumor • ANXA5 • CHEK1 • EIF2A • EIF2S1 • HSPA5

From Concept to Cure: The Road Ahead for Ruthenium-Based Anticancer Drugs. (PubMed, ChemMedChem) - "Among these, Ru complexes, exemplified by BOLD-100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru-based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments."

Journal • Review • Oncology

Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy. (PubMed, Dalton Trans) - "The discovery of cisplatin marked the beginning of the development of anticancer metal-based medications, although the drug's severe side effects have limited its usage in clinical settings. The remarkable antimetastatic and anticancer activity of different ruthenium complexes such as NAMI-A, KP1019, KP1339, etc. reported in the 1980s has bolstered the discovery of ruthenium complexes with various types of ligands for anticancer applications...These findings underscore the promising therapeutic avenues offered by ruthenium-based compounds, particularly in addressing the challenges posed by conventional treatments in refractory or aggressive breast cancer subtypes. Moreover, the review comprehensively integrates a spectrum of ruthenium complexes, spanning traditional metal complexes to nano-based formulations and light-activated variants, underscoring the versatility and adaptability of ruthenium chemistry in breast cancer therapy."

Journal • Breast Cancer • Oncology • Solid Tumor

BOLD-100-001: BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=220 | Recruiting | Sponsor: Bold Therapeutics, Inc. | Active, not recruiting ➔ Recruiting | Phase classification: P1b/2a ➔ P1/2 | N=117 ➔ 220 | Trial completion date: Sep 2024 ➔ Sep 2026 | Trial primary completion date: Dec 2023 ➔ Jun 2026

Combination therapy • Enrollment change • Enrollment open • Metastases • Phase classification • Trial completion date • Trial primary completion date • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Targeting regulated cell death pathways in rhabdomyosarcoma using a trinuclear ruthenium(II) complex (ACS-Fall 2024) - "Platinum-Group Metal (PGM) complexes, particularly those containing ruthenium, present promising avenues for drug discovery, this is exemplified by complexes like BOLD-100, NAMI-A and NKP-1339. Notably, this ruthenium(II) complex also inhibited the migratory ability of metastatic RMS cells and maintained its enhanced cytotoxicity relative to cisplatin in 3D multicellular tumor spheroid models. Mechanistic investigations revealed that the lead ruthenium(II) complex proficiently induced double-stranded DNA damage and triggered various forms of programmed cell death, including both intrinsic and extrinsic apoptotic pathways as well as autophagy, in RMS cells."

Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. (PubMed, Mol Cancer Res) - "These results unveil possible novel therapeutic opportunity for BRAFMT CRC. Implications: BOLD-100 induces BRAFMT-dependent replication stress, and targeted strategies against replication stress (eg. by using ATR inhibitors) in combination with BOLD-100 may serve as a potential novel therapeutic strategy for clinically aggressive BRAFMT CRC."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CHEK1 • CYP1A1

Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 'Metals in Medicine' Gordon Research Conference (PRNewswire) - "Dr. Bazett presented positive Phase 2 clinical results of BOLD-100 in colorectal, biliary tract, and gastric cancers, as well as sharing updates on Bold Therapeutics' unique novel metallotherapeutic screening program and development strategy....Yasmin Borutzki...a close collaborator of Bold Therapeutics, presented a poster on translational research into BOLD-100 entitled: Of Mice and Men: Reverse Translation Investigation of BOLD-100's Mechanism-of-Action."

P2 data • Preclinical • Biliary Tract Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Solid Tumor

BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy (ESMO-GI 2024) - P1b/2a | "Despite previous oxaliplatin treatment, fewer than 5% of pts reported peripheral neuropathy; those reported were G1/2. There remains an unmet need for improved treatment options for patients with mCRC... There remains an unmet need for improved treatment options for patients with mCRC. BOLD-100 + FOLFOX is an active and well-tolerated treatment despite a heavily pretreated population. The mPFS, mOS, ORR and DCR data demonstrate clinical benefit with minimal neuropathy or significant toxicities."

Clinical • Combination therapy • Metastases • P2 data • Colorectal Cancer • Dermatology • Fatigue • Hematological Disorders • Neutropenia • Pain • Pruritus • HSPA5

Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells. (PubMed, Arch Pharm (Weinheim)) - "Among ruthenium complexes studied as anticancer metallodrugs, NKP-1339, NAMI-A, RM175, and RAPTA-C have already entered clinical trials due to their potent antitumor activity demonstrated in preclinical studies and reduced toxicity in comparison with platinum drugs...Coumarin derivative 2a positively regulated the expression and activity of c-Myc and NPM1 in RKO colon carcinoma cells, while the Ru(II) half-sandwich complex 2cRu induced downregulation of AKT and ERK signaling in PANC-1 cells concomitant with reduced intracellular levels of reactive oxygen species. Altogether, our findings indicated that coumarin-modified half-sandwich Ru(II) complexes held potential as anticancer agents against gastrointestinal malignancies."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • MYC • NPM1